ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2013

Abstract Number: 2681

Reduced Fertility In Women With Rheumatoid Arthritis: Influence Of Disease Activity and Medication Use

Jenny Brouwer1,2, Johanna MW Hazes1, Joop SE Laven2 and Radboud JEM Dolhain1, 1Rheumatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands, 2Obstetrics & Gynaecology, division of Reproductive Medicine, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2013

Keywords: Disease Activity, Fertility, Nonsteroidal antiinflammatory drugs (NSAIDs), prednisolone, prednisone and rheumatoid arthritis (RA)

Session Information

Title: Rheumatoid Arthritis - Clinical Aspects IV: Comorbidities in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Many female rheumatoid arthritis (RA) patients who try to conceive have a time to pregnancy (TTP) longer than 12 months.  During this period RA often cannot be treated optimally. As a result, a longer TTP may result in higher chance of permanent joint damage, with a negative impact on social roles. Thus far, no studies on possible causes of the prolonged TTP in RA patients have been reported. In order to optimize care for these women, we aimed to identify clinical factors associated with a prolonged TTP in RA patients.

Methods: From 2002 until 2010, a nationwide prospective cohort study on pregnancy in RA patients (PARA study) was performed. Women with RA according to the 1987 American College of Rheumatology (ACR) criteria were included preconceptionally or during first trimester. All preconceptionally included women were actively trying to become pregnant. To study the effect of various disease characteristics and medications on the TTP, we performed a multivariable Cox regression analysis.

Results: Two-hundred-forty-five patients were included. The mean age was 31.3±3.9 years. The TTP was longer than 12 months in 42% of patients, of whom 40 women(16%) had not gotten pregnant during the follow up period. A longer TTP was related to various variables. Hazard ratios for occurrence of pregnancy were 0.96 (95%CI 0.92-1.00) per year increase in age; 0.52 (0.38-0.70) for nulliparity; 0.81 (0.71-0.93) per point increase in disease activity score (DAS28); 0.61 (0.45-0.83) for preconceptional prednisone use; and 0.66 (0.46-0.94) for non-steroidal anti-inflammatory drug (NSAID) use. Eighty-five patients used prednisone during the preconceptional period. The impact of prednisone use on TTP was dose-dependent, with a significant longer TTP when the daily dose was higher than 7.5 mg. TTP was not affected by smoking, disease duration, rheumatoid factor, anti-citrullinated protein antibodies, past methotrexate use, and preconceptional sulfasalazine use.

Conclusion: TTP in female RA patients is longer if patients are older or nulliparous, have higher disease activity scores, use NSAIDs or use prednisone in a daily dose higher than 7.5 mg daily. Treatment strategies during the preconceptional period should try to maximize suppression of disease activity, taking account of possible negative effects of NSAIDs use and use of higher doses of prednisone.

Disclosures: This study was funded by the Dutch Arthritis Foundation (Reumafonds).


Disclosure:

J. Brouwer,
None;

J. M. Hazes,
None;

J. S. Laven,
None;

R. J. Dolhain,
None.

ACR Meeting Abstracts - https://acrabstracts.org/abstract/reduced-fertility-in-women-with-rheumatoid-arthritis-influence-of-disease-activity-and-medication-use/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology